Breed of mice created for leukemia study

August 22, 2006

A study by U.S. cancer scientists at Ohio State University shows a new strain of mice offers the first real animal model for an incurable chronic leukemia.

The mouse, called the TCL-1 transgenic mouse, develops a malignancy that closely mimics chronic lymphocytic leukemia, or CLL. The lack of such an animal model has previously hampered the development of treatments for CLL, as well as research into its causes and the changes that drive drug resistance.

"This mouse strain shares many of the molecular and genetic features of human CLL, responds to drugs typically used to treat the disease and develops drug resistance that renders treatment ineffective, as often happens in CLL patients," said principal investigator John Byrd, a professor of internal medicine.

Byrd is a specialist in CLL at Ohio State University's Arthur James Cancer Hospital and Richard Solove Research Institute.

"The strain should be extremely valuable for the development and testing of both conventional drugs and those aimed at molecular targets for CLL," he said.

The findings are published in the Aug. 15 issue of the journal Blood.

Copyright 2006 by United Press International

Explore further: Gene shut-down may offer early warning of chronic leukemia

Related Stories

Recommended for you

New blow for 'supersymmetry' physics theory

July 27, 2015

In a new blow for the futuristic "supersymmetry" theory of the universe's basic anatomy, experts reported fresh evidence Monday of subatomic activity consistent with the mainstream Standard Model of particle physics.

A cataclysmic event of a certain age

July 27, 2015

At the end of the Pleistocene period, approximately 12,800 years ago—give or take a few centuries—a cosmic impact triggered an abrupt cooling episode that earth scientists refer to as the Younger Dryas.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.